SCHEMBL2191992

SCHEMBL2191992

CC(C)([C@H]1CCN(c2nc[nH]n2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 5/20 0.46
CYP3A4 P08684 2/20 0.46
NR1I2 O75469 1/20 0.45
AKR1B1 P15121 1/20 0.39
POLB P06746 1/20 0.37
DRD2 P14416 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
AKR1C3 P42330 1/20 0.36
HSD11B1 P28845 1/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HTR6 P50406 3/20 0.36
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2190203 0.87 CACNA1B (0.47) CACNA1BCYP3A4NR1I2AKR1B1POLB
SCHEMBL2187285 0.87 CACNA1B (0.47) CACNA1BCYP3A4NR1I2AKR1B1POLB
SCHEMBL2188500 0.84 CACNA1B (0.45) CACNA1BCYP3A4NR1I2POLBDRD2
SCHEMBL2187708 0.83 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2HSD11B1LMNA
SCHEMBL1728002 0.83 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2HSD11B1LMNA
SCHEMBL2190746 0.83 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2HSD11B1LMNA
SCHEMBL2188633 0.82 CYP3A4 (0.50) CACNA1BCYP3A4NR1I2POLBLMNA
SCHEMBL2191587 0.82 CACNA1B (0.47) CACNA1BCYP3A4NR1I2POLBHSD11B1
SCHEMBL2191790 0.81 CACNA1B (0.49) CACNA1BCYP3A4NR1I2POLBDRD2
SCHEMBL2190018 0.81 CACNA1B (0.49) CACNA1BCYP3A4NR1I2POLBDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.